Company / R&D Expense
Esperion Therapeutics, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$47.9M
FY2025
5-year range
$46.2M / $118.9M
FY2021-FY2025
Trend
+3.5%
vs FY2024
Sector context
#181 of 210
Health Care
What the data says
Esperion Therapeutics, Inc.'s r&d expense of $48M is lower than 86% of companies in the Health Care sector (FY2025). R&D Expense returned to growth in FY2025 after 2 years of decline, reaching $48M.
Based on SEC 10-K filings.
$48M in FY2025 with a 5-year CAGR of -20.1%.
Declined from $86M to $48M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -26.2%
- 5-Year CAGR
- -20.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 14% in Health CareTop 86% of 210This company $47.9M Sector average $644.1M
▼
-92.6% below sector average
Key checks
Key Insights
- 5-year CAGR of -20.1%, indicating a declining trend.
- In FY2025, r&d expense increased 3.5% year-over-year.
- Ranks #181 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score -1.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $47.9M | +3.5% |
| FY2024 | $46.2M | -46.3% |
| FY2023 | $86.1M | -27.6% |
| FY2022 | $118.9M | +12.2% |
| FY2021 | $106.0M | -27.9% |
| FY2020 | $146.9M | -16.3% |
| FY2019 | $175.6M | +2.4% |
| FY2018 | $171.5M | +16.2% |
| FY2017 | $147.6M | +155.1% |
| FY2016 | $57.9M | +94.2% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026